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 Purpose.—To update key recommendations of the
American Society of Clinical Oncology/College of Amer-
ican Pathologists estrogen receptor (ER) and progesterone
receptor (PgR) testing in breast cancer guideline.
Methods.—A multidisciplinary international Expert Pan-
el was convened to update the clinical practice guideline
recommendations informed by a systematic review of the
medical literature.
Recommendations.—The Expert Panel continues to
recommend ER testing of invasive breast cancers by
validated immunohistochemistry as the standard for
predicting which patients may benefit from endocrine
therapy, and no other assays are recommended for this
purpose. Breast cancer samples with 1% to 100% of tumor
nuclei positive should be interpreted as ER positive.
However, the Expert Panel acknowledges that there are
limited data on endocrine therapy benefit for cancers with
1% to 10% of cells staining ER positive. Samples with
these results should be reported using a new reporting
category, ER Low Positive, with a recommended comment.
A sample is considered ER negative if , 1% or 0% of
tumor cell nuclei are immunoreactive. Additional strate-
gies recommended to promote optimal performance,
interpretation, and reporting of cases with an initial low
to no ER staining result include establishing a laboratory-
specific standard operating procedure describing addition-
al steps used by the laboratory to confirm/adjudicate
results. The status of controls should be reported for cases
with 0% to 10% staining. Similar principles apply to PgR
testing, which is used primarily for prognostic purposes in
the setting of an ER-positive cancer. Testing of ductal
carcinoma in situ (DCIS) for ER is recommended to
determine potential benefit of endocrine therapies to
reduce risk of future breast cancer, while testing DCIS
for PgR is considered optional. Additional information can
be found at www.asco.org/breast-cancer-guidelines.
(Arch Pathol Lab Med. 2020;144:545–563; doi: 10.5858/
arpa.2019-0904-SA)
INTRODUCTION
F irst released in 2010, the American Society of ClinicalOncology (ASCO)/College of American Pathologists
(CAP) estrogen receptor (ER) and progesterone receptor
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THE BOTTOM LINE—Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical
Oncology/College of American Pathologists Guideline Update
Guideline Questions
1. What are the optimum quality assurance (QA), tissue handling, scoring system, and reporting for determining potential benefit from
endocrine therapy?
2. What additional strategies can promote optimal performance, interpretation, and reporting of immunohistochemistry (IHC) assays,
particularly in cases with low estrogen receptor (ER) expression?
3. Are other ER expression assays acceptable for identifying patients likely to benefit from endocrine therapy?
4. Should ductal carcinoma in situ (DCIS) be routinely tested for hormone receptors?
Target Population
Patients with breast cancer.
Target Audience
Medical oncologists, pathologists, surgeons, radiation oncologists, and patients and their caregivers.
Methods
A multidisciplinary Expert Panel was convened to update the clinical practice guideline recommendations based on a systematic review of
the medical literature.
Recommendations
Recommendation 1.1: Optimal algorithm for ER/progesterone receptor testing. Samples with 1% to 100% of tumor nuclei positive for ER
or progesterone receptor (PgR) are interpreted as positive. For reporting of ER (not PgR), if 1% to 10% of tumor cell nuclei are
immunoreactive, the sample should be reported as ER Low Positive with a recommended comment (Table 2; Figure 1). A sample is
considered negative for ER or PgR if , 1% or 0% of tumor cell nuclei are immunoreactive. A sample may be deemed uninterpretable for
ER or PgR if the sample is inadequate (insufficient cancer or severe artifacts present, as determined at the discretion of the pathologist), if
external and internal controls (if present) do not stain appropriately, or if preanalytic variables have interfered with the assay’s accuracy
(Figures 1–4). Clinicians should be aware of and be able to discuss with patients the limited data on ER Low Positive cases and issues with
test results that are close to a positive threshold (Type: Evidence based; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 1.2: Optimal testing conditions (no change). Large (preferably multiple) core biopsies of tumor are preferred for testing if
they are representative of the tumor (grade and type) at resection. Accession slip and report must include guideline-detailed elements
(Type: Evidence based; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 1.3: Optimal tissue handling requirements (no change). Time from tissue acquisition to fixation should be as short as
possible. Samples for ER and PgR testing are fixed in 10% neutral buffered formalin (NBF) for 6 to 72 hours. Samples should be sliced at
5-mm intervals after appropriate gross inspection and margin designation and placed in sufficient volume of NBF to allow adequate
tissue penetration. If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory
immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.
As in the American Society of Clinical Oncology/College of American Pathologists (CAP) human epidermal growth factor receptor 2
guideline, use of unstained slides cut more than 6 weeks before analysis is not recommended. Time tissue is removed from patient, time
tissue is placed in fixative, duration of fixation, and fixative type must be recorded and noted on accession slip or in report (Type:
Evidence based; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 1.4: Optimal internal validation procedures (change anticipated). This topic is deferred to the forthcoming CAP
guideline update of the principles of analytic validation of IHC assays, once available. There should be initial test validation/verification
prior to reporting any clinical samples. Prior to that, previously recommended principles apply, as described by Fitzgibbons et al12 and
more recently Torlakovic et al13 (Type: Evidence based; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 1.5: Optimal internal QA procedures. Ongoing quality control and equipment maintenance are required. Initial and
ongoing laboratory personnel training and competency assessment should be performed. Standard operating procedures (SOPs) should be
used that include routine use of external control materials with each batch of testing and routine evaluation of internal normal epithelial
elements or the inclusion of normal breast sections (or other appropriate control) on each tested slide, wherever possible. External
controls should include negative and positive samples as well as samples with lower percentages of ER expression (such as tonsil). On-
slide controls are recommended. Regular, ongoing assay reassessment should be done at least semiannually (as described in Fitzgibbons
et al12). Revalidation is needed whenever there is a significant change to the test system.13 Ongoing competency assessment and
education of pathologists are required (Type: Evidence based; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 1.6: Optimal external proficiency assessment. The laboratory performing ER and PgR testing must participate in external
proficiency testing or alternative performance assessment as required by its accrediting organization (Type: Evidence based; Evidence
quality: High; Strength of recommendation: Strong).
Recommendation 1.7: Optimal laboratory accreditation. On-site inspection every other year should be undertaken, with annual
requirement for self-inspection (Type: Informal consensus; Evidence quality: Intermediate; Strength of recommendation: Moderate).
Recommendation 2.1. Laboratories should include ongoing quality control using SOPs for test evaluation prior to scoring (readout) and
interpretation of any case as defined in the checklist in Figure 1 (Type: Informal consensus; Evidence quality: High; Strength of
recommendation: Strong).
Recommendation 2.2. Interpretation of any ER result should include evaluation of the concordance with the histologic findings of each
case. Clinicians should also be aware of when results are highly unusual/discordant and work with pathologists to attempt to resolve or
explain atypical reported findings; Table 3 is an aid in this process (Type: Informal consensus; Evidence quality: High; Strength of
recommendation: Strong).
Recommendation 2.3. Laboratories should establish and follow an SOP stating the steps the laboratory takes to confirm or adjudicate ER
results for cases with weak stain intensity or  10% of cells staining; Supplemental Digital Content Data Supplement 2, Figure 1
provides an example SOP (Type: Informal consensus; Evidence quality: High; Strength of recommendation: Strong).
Recommendation 2.4. The status of internal controls should be reported for cases with 0% to 10% staining. For cases with these results
without internal controls present and with positive external controls, an additional report comment is recommended (Table 2) (Type:
Informal consensus; Evidence quality: High; Strength of recommendation: Strong).
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(PgR) testing guideline is aimed at improving the analytic
performance and diagnostic accuracy of ER and PgR testing
and their clinical utility as biomarkers for the management
of women with primary breast cancer.1,2 The guideline
focuses entirely on immunohistochemical testing, as this
reflects the near exclusive use of this approach in
contemporary practice. The Expert Panel (Appendix) recon-
vened to consider evidence for changes in laboratory and
clinical practice or the emergence of new data that might
require an update in this guideline. The importance of the
accurate assessment (protocols and readout) and interpre-
tation of ER and PgR expression is emphasized by more
than 1,000,000 women per year worldwide diagnosed with
primary breast cancer and tested for these receptors. Studies
using contemporary populations note increases in the
proportion of breast cancers that are ER positive, with
overall rates of between 79% and 84% of breast cancers
(with higher ER-positive rates occurring in postmenopausal
subpopulations).3–9 While ER-positive rates are influenced
by population-dependent variables (eg, age, race, screening,
birth rate, and so on), increased analytic sensitivity of assay
protocols due to adherence to previously published guide-
lines, newer detection methods, more sensitive primary
antibodies, and protocol design changes after feedback
provided by external quality assessment may also have
contributed to this increase.
Utility of ER and PgR Testing and Threshold Setting
The Expert Panel acknowledged that hormone receptor
testing in breast cancer currently serves other purposes
beyond identification of which patients may benefit from
endocrine-specific strategies for breast cancer treatment.
These include the following: 1) to assist in classification of
breast cancer for the most appropriate overall treatment
pathway (with most treatment guidelines centered around
ER-positive v ER-negative pathways); 2) to assist in
prognostication, such as classification of breast cancer, for
the most appropriate overall prognostic stage group (eg,
American Joint Committee on Cancer [AJCC] eighth edition
prognostic stage groupings)10; and 3) as a diagnostic aid in
metastatic breast cancer. The Expert Panel acknowledged
that a well-performed ER assay should be useful in each of
these scenarios. It should be noted, however, that the
specific thresholds for a positive versus a negative test result
in this guideline are based on the data supporting the
optimal threshold to use ER status as a predictive marker for
endocrine treatment strategies in breast cancer.
There is unequivocal evidence that patients with cancers
devoid of ER expression do not benefit from endocrine
treatment.11 The challenge has been and remains defining
an ER expression cutoff that best segregates patients who
may derive meaningful clinical benefit from endocrine
therapy strategies from those who will not. The 2010
guideline recommended that invasive breast cancers be
considered positive if at least 1% of cancer nuclei stain
positive and that patients with such cancers be considered
for endocrine therapy, while such therapy should be
withheld from patients with cancers with , 1% staining.
It was also noted that it is reasonable for oncologists to
discuss the pros and cons of endocrine therapy with patients
whose cancers contain low levels of ER by immunohisto-
chemistry (IHC; 1%–10% weakly positive cells) and to make
a decision based on the totality of information about the
individual case. This recommendation is reaffirmed in this
2019 update (Clinical Question 1).
The utility of PgR testing continues to be largely
prognostic in the ER-positive population, but testing using
principles similar to those used in ER testing is still
recommended for invasive breast cancers.
Current Status of ER and PgR Testing and Focus Areas for
Improvement
The Expert Panel examined data on the quality of
hormone receptor testing in breast cancer in the years since
the 2010 guideline was first published to identify areas
where additional guidance might be beneficial. There has
been an apparent improvement in the overall quality of
hormone receptor testing in breast cancer and improved
monitoring of performance. While interlaboratory variability
for ER and PgR results has decreased, some variability
continues to exist, emphasizing the need for continued
publication of antibody- and method-specific results,
guidance on best practices, and continued monitoring of
pathologist scoring (readout) performance to improve
reproducibility and reduce interobserver variation.
Handling of Cases With Low ER Expression
Although the recent literature supports reaffirming the
current guideline recommendations overall (Clinical Question
1), there has been increased concern over the proper handling
of cases with low ER expression. Such cases with low levels of
ER expression are included in ER-positive treatment and
prognostic algorithms designed for a majority of cases, which
have strong ER expression. Although uncommon (accounting
for only 2%–3% of ER-positive cancers), cancers with 1% to
10% cells staining for ER present particular clinical challenges.
For example, should a high-grade cancer with 1% to 10% ER
expression, 0% PgR expression, and human epidermal growth
factor receptor 2 (HER2)negative results be considered for
treatments designed for triple-negative cancers? One of the
THE BOTTOM LINE—Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical
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Recommendation 3. Validated IHC is the recommended standard test for predicting benefit from endocrine therapy. No other assay types are
recommended as the primary screening test for this purpose (Type: Evidence based; Evidence quality: High; Strength of recommendation:
Strong).
Recommendation 4. ER testing in cases of newly diagnosed DCIS (without associated invasion) is recommended to determine potential
benefit of endocrine therapies to reduce risk of future breast cancer. PgR testing is considered optional (Type: Evidence based; Evidence
quality: Intermediate; Strength of recommendation: Moderate).
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the
opportunity to participate. More information, including a supplement with evidence tables, slide sets, and clinical tools and resources, is
available at www.asco.org/breast-cancer-guidelines. The Methodology Manual (available at www.asco.org/guideline-methodology) provides
additional information about the methods used to develop this guideline. Patient information is available at www.cancer.net.
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Table 1. Summary of All Recommendations
2010 Recommendation Updated Recommendation
Clinical Question 1. What are the optimum QA, specimen handling, positive threshold, scoring system, and reporting for determining
potential benefit from endocrine therapy?
Optimal algorithm for ER/PgR testing Optimal algorithm for ER/PgR testing
Positive for ER or PgR if finding that  1% of tumor cell
nuclei are immunoreactive.
Samples with 1%–100% of tumor nuclei positive for ER or PgR are
interpreted as positive.
Negative for ER or PgR if finding that , 1% of tumor
cell nuclei are immunoreactive in the presence of
evidence that the sample can express ER or PgR
(positive intrinsic controls are seen).
For reporting of ER (not PgR), if 1%–10% of tumor cell nuclei are
immunoreactive, the sample should be reported as ER Low Positive with a
recommended comment (Table 2; Figure 1).
Uninterpretable for ER or PgR if finding that no tumor
nuclei are immunoreactive and that internal epithelial
elements present in the sample or separately
submitted from the same sample lack any nuclear
staining.
A sample is considered negative for ER or PgR if , 1% or 0% of tumor cell
nuclei are immunoreactive.
A sample may be deemed uninterpretable for ER or PgR if the sample is
inadequate (insufficient cancer or severe artifacts present, as determined at
the discretion of the pathologist), if external and internal controls (if
present) do not stain appropriately, or if preanalytic variables have
interfered with the assay’s accuracy (Figures 1 to 4).
Clinicians should be aware of and be able to discuss with patients the
limited data on ER–low positive cases and issues with test results that are
close to a positive threshold.
Optimal testing conditions Optimal testing conditions (no changes)
Large (preferably multiple) core biopsies of tumor are
preferred for testing if they are representative of the
tumor (grade and type) at resection.
Large (preferably multiple) core biopsies of tumor are preferred for testing if
they are representative of the tumor (grade and type) at resection.
Accession slip and report must include guideline-
detailed elements.
Accession slip and report must include guideline-detailed elements.
Optimal tissue handling requirements Optimal tissue handling requirements (no changes)
Time from tissue acquisition to fixation should be as
short as possible. Samples for ER and PgR testing are
fixed in 10% NBF for 6 to 72 hours. Samples should
be sliced at 5-mm intervals after appropriate gross
inspection and margins designation and placed in
sufficient volume of NBF to allow adequate tissue
penetration. If tumor comes from remote location, it
should be bisected through the tumor on removal and
sent to the laboratory immersed in a sufficient
volume of NBF. Cold ischemia time, fixative type,
and time the sample was placed in NBF must be
recorded.
Time from tissue acquisition to fixation should be as short as possible.
Samples for ER and PgR testing are fixed in 10% NBF for 6 to 72 hours.
Samples should be sliced at 5-mm intervals after appropriate gross
inspection and margins designation and placed in sufficient volume of
NBF to allow adequate tissue penetration. If tumor comes from remote
location, it should be bisected through the tumor on removal and sent to
the laboratory immersed in a sufficient volume of NBF. Cold ischemia
time, fixative type, and time the sample was placed in NBF must be
recorded.
As in the ASCO/CAP HER2 guideline, use of slides cut
more than 6 weeks before analysis is not
recommended.
As in the ASCO/CAP HER2 guideline, use of unstained slides cut more than
6 weeks before analysis is not recommended.
The time tissue is removed from patient, time tissue is
placed in fixative, duration of fixation, and fixative
type must be recorded and noted on accession slip or
in report.
The time tissue is removed from patient, time tissue is placed in fixative,
duration of fixation, and fixative type must be recorded and noted on
accession slip or in report.
Optimal internal validation procedures Optimal internal validation procedures
Internal validation must be done before test is offered;
see separate article on testing validation (Fitzgibbons
et al12).
This topic is deferred to the forthcoming CAP guideline update, Principles of
Analytic Validation of IHC Assays, once available. There should be initial
test validation/verification prior to reporting any clinical samples. Prior to
that, previously recommended principles apply (Fitzgibbons et al12 and more
recently Torlakovic et al13).
Validation must be done using a clinically validated ER
or PgR test method.
Revalidation should be done whenever there is a
significant change to the test system, such as a
change in the primary antibody clone or introduction
of new antigen retrieval or detection systems.
Optimal internal QA procedures Optimal internal QA procedures
Ongoing quality control and equipment maintenance. Ongoing quality control and equipment maintenance are required.
Initial and ongoing laboratory personnel training and
competency assessment.
Initial and ongoing laboratory personnel training and competency
assessment should be performed.
Use of SOPs, including routine use of external control
materials with each batch of testing and routine
evaluation of internal normal epithelial elements or
the inclusion of normal breast sections on each tested
slide, wherever possible.
SOPs should be used that include routine use of external control materials
with each batch of testing and routine evaluation of internal normal
epithelial elements or the inclusion of normal breast sections (or other
appropriate control) on each tested slide, wherever possible. External
controls should include negative and positive samples as well as samples
with lower percentages of ER expression (such as tonsil). On-slide controls
are recommended.
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most common questions asked during the open comment
period for the ASCO/CAP HER2 guideline update, which
included a question on issues related to the 2010 ER/PgR
testing guideline, was what to do clinically with ER Low
Positive cancers.
Cases with weak or low ER or PgR staining are also noted
to be particular challenges for test reproducibility due to a
variety of factors (reproducibility of scoring close to a
threshold, particular sensitivity to preanalytic [eg, cold
ischemic time, fixation type and time, and so on] and
analytic factors [eg, antibody used, methodology], hetero-
geneity of expression, and lack of standardized low
ERexpressing controls). Clinical Question 2 of this update
focuses on strategies to promote optimal performance,
interpretation, and reporting of all cases, and new recom-
mendations for interpreting and reporting cases with weak
or  10% ER expression are provided.
Given recent advances in alternative testing strategies, the
guideline update also addresses the question of whether
evolving genomic/molecular and image analysis methods
are ready to be incorporated into routine testing for ER and
PgR (Clinical Question 3).
All the recommendations apply to patients with invasive
breast cancer; however, recommendations on hormone
receptor testing in ductal carcinoma in situ (DCIS) are also
offered (Clinical Question 4).
GUIDELINE QUESTIONS
This update specifically addresses 4 clinical questions
raised after the publication of the 2010 guideline:
1. What are the optimum quality assurance (QA), tissue
handling, scoring system, and reporting for determining
potential benefit from endocrine therapy?
Table 1. Continued
2010 Recommendation Updated Recommendation
Regular, ongoing assay reassessment should be done at
least semiannually (as described by Fitzgibbons et
al12 and more recently Torlakovic et al13); revalidation
is needed whenever there is a significant change to
the test system.
Regular, ongoing assay reassessment should be done at least semiannually
(as described in Fitzgibbons et al12). Revalidation is needed whenever
there is a significant change to the test system.13
Ongoing competency assessment and education of
pathologists.
Ongoing competency assessment and education of pathologists is required.
Optimal external proficiency assessment Optimal external proficiency assessment
Mandatory participation in external proficiency testing
program with at least two testing events (mailings) per
year.
The laboratory performing ER and PgR testing must participate in external
proficiency testing or alternative performance assessment as required by its
accrediting organization.
Satisfactory performance requires at least 90% correct
responses on graded challenges for either test.
Optimal laboratory accreditation Optimal laboratory accreditation
On-site inspection every other year with annual
requirement for self-inspection.
On-site inspection every other year should be undertaken with annual
requirement for self-inspection.
Clinical Question 2. What additional strategies can promote optimal performance, interpretation, and reporting of IHC assays, particularly
in cases with low ER expression?
No specific recommendations were specified in 2010
for low ER expression cases.
Laboratories should include ongoing quality control using SOPs for test
evaluation prior to scoring (readout) and interpretation of any case, as
defined in the checklist in Figure 1.
Interpretation of any ER result should include evaluation of the concordance
with the histologic findings of each case. Clinicians should also be aware
of when results are highly unusual/discordant and work with pathologists
to attempt to resolve or explain atypical reported findings (Table 3 is an
aid in this process).
Laboratories should establish and follow an SOP stating the steps the
laboratory takes to confirm or adjudicate ER results for cases with weak
stain intensity or  10% of cells staining (Supplemental Digital Content
Data Supplement 2, Figure 1 provides an example SOP).
The status of internal controls should be reported for cases with 0%–10%
staining. For cases with these results without internal controls present and
with positive external controls, an additional report comment is
recommended (Table 2).
Clinical Question 3. Are other ER expression assays acceptable for identifying patients likely to benefit from endocrine therapy?
No assays other than IHC are recommended as testing
platforms.
Validated IHC is the recommended standard test for predicting benefit from
endocrine therapy. No other assay types are recommended as the primary
screening test for this purpose.
Clinical Question 4. Should DCIS be routinely tested for hormone receptors?
ER and PgR testing of DCIS is optional (no formal
recommendation made to test or not test).
ER testing in cases of newly diagnosed DCIS (without associated invasion) is
recommended to determine potential benefit of endocrine therapies to
reduce risk of future breast cancer; PgR testing is considered optional.
Abbreviations: ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; DCIS, ductal carcinoma in situ; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NBF, neutral buffered formalin; PgR, progesterone
receptor; QA, quality assurance; SOP, standard operating procedure.
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2. What additional strategies can promote optimal perfor-
mance, interpretation, and reporting of IHC assays,
particularly in cases with low ER expression?
3. Are other ER expression assays acceptable for identifying
patients likely to benefit from endocrine therapy?
4. Should DCIS be routinely tested for hormone receptors?
METHODS
This ASCO and CAP clinical practice guideline update provides
revised recommendations with a comprehensive discussion of the
relevant literature for these specific recommendations. The full
guideline and additional information are available at www.asco.
org/breast-cancer-guidelines; this guideline is also available on the
Archives Web site at www.archivesofpathology.org. The complete
list of recommendations is in Table 1, including the updated
recommendations.
Guideline Update Process
This systematic reviewbased guideline product was developed
by a multidisciplinary Expert Panel, which included a patient
representative and an ASCO guideline staff member with health
research methodology expertise. PubMed and the Cochrane
Library were searched for randomized controlled trials, systematic
reviews, meta-analyses, and clinical practice guidelines for the
period from January 1, 2008, of the previous update through April
30, 2019. The disease and intervention search terms were those that
were used for the 2010 guideline. The searches identified 4,897
abstracts, and ultimately, 87 papers met the selection criteria.11,14–99
Articles were selected for inclusion in the systematic review of the
evidence based on the following criteria:
 The population included adults with a new diagnosis of breast
cancer or a recurrence
 Studies of ER or PgR testing by IHC
 Primary end points considered positive and negative predictive
values of assays used to accurately determine hormone receptor
status, including (but not necessarily limited to): specific assay
performance, technique, standardization attempted, QA, profi-
ciency testing, individual or institutional training, or improve-
ment in assay results based on interventions
Articles were excluded from the systematic review if they were
(1) meeting abstracts not subsequently published in peer-reviewed
journals; (2) editorials, commentaries, letters, news articles, case
reports, or narrative reviews; or (3) published in a non-English
language.
The Expert Panel met in person at ASCO headquarters to update
the guideline. The updated ASCO/CAP guideline was circulated in
draft form, reviewed, and approved by the Expert Panel. ASCO’s
Clinical Practice Guidelines Committee (CPGC) reviewed and
approved the final document. For CAP, an independent review
panel was assembled to review and approve the guideline. The
independent review panel was masked to the Expert Panel and was
vetted through the conflict-of-interest process. All funding for the
administration of the project was provided by ASCO.
Guideline Disclaimer
The clinical practice guidelines and other guidance published
herein are provided by the American Society of Clinical Oncology,
Inc. (‘‘ASCO’’) and the College of American Pathologists (CAP) to
assist providers in clinical decision making. The information therein
should not be relied upon as being complete or accurate, nor
should it be considered as inclusive of all proper treatments or
methods of care or as a statement of the standard of care. With the
rapid development of scientific knowledge, new evidence may
emerge between the time information is developed and when it is
published or read. The information is not continually updated and
may not reflect the most recent evidence. The information
addresses only the topics specifically identified therein and is not
applicable to other interventions, diseases, or stages of diseases.
This information does not mandate any particular course of medical
care. Further, the information is not intended to substitute for the
independent professional judgment of the treating provider, as the
information does not account for individual variation among
patients. Recommendations reflect high, moderate or low confi-
dence that the recommendation reflects the net effect of a given
course of action. The use of words like ‘‘must,’’ ‘‘must not,’’
‘‘should,’’ and ‘‘should not’’ indicate that a course of action is
recommended or not recommended for either most or many
patients, but there is latitude for the treating physician to select
other courses of action in individual cases. In all cases, the selected
course of action should be considered by the treating provider in
the context of treating the individual patient. Use of the
information is voluntary. ASCO and the CAP provide this
information on an ‘‘as is’’ basis, and make no warranty, express
or implied, regarding the information. ASCO and the CAP
specifically disclaim any warranties of merchantability or fitness
for a particular use or purpose. ASCO and the CAP assume no
responsibility for any injury or damage to persons or property
arising out of or related to any use of this information or for any
errors or omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with ASCO’s
Conflict of Interest Policy Implementation for Clinical Practice
Guidelines (‘‘Policy,’’ found at http://www.asco.org/rwc) as agreed
upon with CAP. All members of the Expert Panel completed
ASCO’s disclosure form, which requires disclosure of financial and
other interests, including relationships with commercial entities
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RECOMMENDATIONS
Clinical Question 1
What are the optimum QA, testing conditions, tissue
handling, scoring system, and reporting for determining
potential benefit from endocrine therapy?
Recommendation 1.1. Optimal Algorithm for ER/PgR
testing.—Samples with 1% to 100% of tumor nuclei
positive for ER or PgR are interpreted as positive. For
reporting of ER (not PgR), if 1% to 10% of tumor cell nuclei
are immunoreactive, the sample should be reported as ER
Low Positive with a recommended comment (Table 2;
Figure 1). A sample is considered negative for ER or PgR if
, 1% or 0% of tumor cell nuclei are immunoreactive. A
sample may be deemed uninterpretable for ER or PgR if the
sample is inadequate (insufficient cancer or severe artifacts
present, as determined at the discretion of the pathologist),
if external and internal controls (if present) do not stain
appropriately, or if preanalytic variables have interfered with
the assay’s accuracy (Figures 1 through 4). Clinicians should
be aware of and be able to discuss with patients the limited
data on ERlow positive cases and issues with test results
that are close to a positive threshold (Type: Evidence based;
Evidence quality: High; Strength of recommendation:
Strong).
Recommendation 1.2. Optimal Testing Conditions (no
change).—Large (preferably multiple) core biopsies of
tumor are preferred for testing if they are representative of
the tumor (grade and type) at resection. Accession slip and
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report must include guideline-detailed elements (Type:
Evidence based; Evidence quality: High; Strength of
recommendation: Strong).
Recommendation 1.3. Optimal Tissue Handling Re-
quirements (no change).—Time from tissue acquisition to
fixation should be as short as possible. Samples for ER and
PgR testing are fixed in 10% neutral buffered formalin (NBF)
for 6 to 72 hours. Samples should be sliced at 5-mm
intervals after appropriate gross inspection and margin
designation and placed in sufficient volume of NBF to allow
adequate tissue penetration. If tumor comes from remote
location, it should be bisected through the tumor on
removal and sent to the laboratory immersed in a sufficient
volume of NBF. Cold ischemia time, fixative type, and time
the sample was placed in NBF must be recorded. As in the
ASCO/CAP HER2 guideline, use of unstained slides cut
more than 6 weeks before analysis is not recommended.
Time tissue is removed from patient, time tissue is placed in
fixative, duration of fixation, and fixative type must be
recorded and noted on accession slip or in report (Type:
Evidence based; Evidence quality: High; Strength of
recommendation: Strong).
Recommendation 1.4. Optimal Internal Validation
Procedures (change anticipated).—This topic is deferred
to the forthcoming CAP guideline update of the principles
of analytic validation of IHC assays, once available. There
should be initial test validation/verification prior to reporting
any clinical samples. Prior to that, previously recommended
principles apply, as described by Fitzgibbons et al12 and
more recently Torlakovic et al13 (Type: Evidence based;
Evidence quality: High; Strength of recommendation:
Strong).
Recommendation 1.5. Optimal Internal QA Proce-
dures.—Ongoing quality control and equipment mainte-
nance are required. Initial and ongoing laboratory personnel
training and competency assessment should be performed.
Standard operating procedures (SOPs) should be used that
include routine use of external control materials with each
batch of testing and routine evaluation of internal normal
epithelial elements or the inclusion of normal breast
sections (or other appropriate control) on each tested slide,
wherever possible. External controls should include negative
and positive samples as well as samples with lower
percentages of ER expression (such as tonsil). On-slide
controls are recommended.
Regular, ongoing assay reassessment should be done at
least semiannually (as described by Fitzgibbons et al12).
Revalidation is needed whenever there is a significant
change to the test system.13 Ongoing competency assess-
ment and education of pathologists are required (Type:
Evidence based; Evidence quality: High; Strength of
recommendation: Strong).
Recommendation 1.6. Optimal External Proficiency
Assessment.—The laboratory performing ER and PgR
testing must participate in external proficiency testing or
alternative performance assessment as required by its
accrediting organization (Type: Evidence based; Evidence
quality: High; Strength of recommendation: Strong).
Recommendation 1.7. Optimal Laboratory Accredita-
tion.—On-site inspection every other year should be
undertaken, with annual requirement for self-inspection
(Type: Informal consensus; Evidence quality: Intermediate;
Strength of recommendation: Moderate).
Literature Review and Analysis.—Data from proficiency
testing and quality control programs indicate that an overall
improvement in the quality and reproducibility of ER and
PgR testing in breast cancer has occurred over time. This is
likely the result of improvements in standardization of
preanalytic, analytic, and postanalytic factors, as well as
increases in antibody sensitivity, allowing the Expert Panel
to reaffirm the original 2010 recommendations on specimen
handling, optimal testing conditions, and QA.100,101
Much of the focus of the update review involved
reexamining the data on the optimal ER positive threshold
and scoring systems to determine potential benefit from
endocrine therapy. There are limited new data on this
threshold, as most randomized clinical trials addressing the
topic took place in the 1990s. There is little argument about
the potential benefit of endocrine therapy in patients with
cancers with . 10% ER expression or the lack of potential
benefit for cancers with , 1% ER expression. However,
there are much more limited data on the 2% to 3% of
cancers that are low ER expressers (most often defined as
1%–10% ER-positive cells by IHC) and their potential
benefit from endocrine therapy. In 2011, a large meta-
analysis was published of 20 prior clinical trials with more
than 200,000 women-years of follow-up, reporting on the
benefit of 5 years of tamoxifen according to ER and PgR
levels as measured by ligand-binding assay (LBA).11 More
than 50,000 women-years of follow-up were available for
women with tumors having ,10 fmol ER/mg protein, and
no evidence of benefit was apparent. However, patients
with cancers with low levels of ER (10–20 fmol ER/mg
protein) had their likelihood of recurrence reduced by one
third with the addition of approximately 5 years of
tamoxifen (risk ratio [RR], 0.67; SE, 0.08). Of note, while
benefit increased somewhat with higher ER levels, the
proportional effect at the highest ER levels (. 200 fmol/mg)
was only slightly better than that at weak ER levels (RR,
0.52; SE, 0.07). Although there are limited data from
prospective randomized trials comparing the predictive
power of LBAs with the standard IHC methods of ER
assessment in routine use, multiple studies support high
rates of agreement between these assays.98,99,102–104 In most
Table 2. Additional Recommended Reporting Comments for Specific Scenarios
Result Additional Recommended Comment
1%–10% cells staining The cancer in this sample has a low level (1%–10%) of ER expression by IHC. There are limited data on the
overall benefit of endocrine therapies for patients with low level (1%–10%) ER expression, but they
currently suggest possible benefit, so patients are considered eligible for endocrine treatment. There are
data that suggest invasive cancers with these results are heterogeneous in both behavior and biology and
often have gene expression profiles more similar to ER-negative cancers.
No internal controls and
ER is 0%–10%
No internal controls are present, but external controls are appropriately positive. If needed, testing another
specimen that contains internal controls may be warranted for confirmation of ER status.
Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry.
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Figure 1. Recommendations for scoring (readout) and interpretation of immunohistochemistry (IHC) test to determine estrogen receptor (ER)
status in breast cancers. For progesterone receptor (PgR) testing, the same overall interpretation principles apply, but the reporting elements are only
recommended for ER testing. PgR should be interpreted as either positive (if 1%–100% of cells have nuclear staining) or negative (if , 1% or 0% of
cells have nuclear staining), with the overall percentage and intensity of staining reported. (*) Hormone receptor testing should only be done with a
validated method and with appropriate laboratory procedures, including ongoing assay monitoring and pathologist competency assessment. (†) If no
internal controls are present but external controls are positive, include comment: ‘‘No internal controls are present, but external controls
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studies, a  10 fmol/mg threshold corresponded best (albeit
imperfectly) with  1% of cells with nuclear ER staining by
IHC, the current recommended IHC cutoff for ER positiv-
ity.11,97,105
Complicating the understanding of low ER-expressing
cancers are data indicating that these cancers are a
heterogeneous group but often have clinical outcomes and
biologic/molecular profiles that are often more similar to
those of ER-negative cancers.91–97,106 However, none of
these retrospective and nonrandomized studies can address
the potential benefit of endocrine therapy for at least some
patients in the 1% to 10% ER-positive group. The Expert
Panel acknowledges the data from these studies provide
support that cancers with low ER expression may be
biologically distinct from high ER expressers and that the
1% threshold for ER positivity may not uniformly predict
differences in prognosis, chemotherapy benefit, or regimen,
or define a specific molecular subtype. Most important, low
ER expression status has not been validated for these
purposes.
Given the relatively low toxicity of endocrine therapy, the
desire to minimize false-negative results, and the available
(although limited) data supporting potential benefit even in
cases with as low as 1% to 10% positivity, the Expert Panel
continues to recommend  1% nuclear ER staining by IHC
as the threshold for reporting a positive ER result to predict
potential clinical benefit from endocrine therapy treatments.
However, cases with 1% to 10% staining should be reported
as ER Low Positive, with a recommended comment
explaining the more limited clinical data, heterogeneous
behavior, and biology of this subgroup of ER-positive
cancers. As in 2010, the Expert Panel recommends that
oncologists discuss the pros and cons of endocrine therapy
with patients whose cancers contain low levels of ER by IHC
and base decisions on the totality of information available
about an individual case. Laboratories should continue to
report both the percentage and intensity of hormone
receptor staining in addition to the test interpretation as
positive, low positive, or negative. Clinical Question 2
addresses additional steps that should be taken to promote
optimal performance and interpretation, especially in the
weak or low ERexpressing cases.
Controls
Control tissues are essential for evaluating assay perfor-
mance. External controls should include negative and
positive samples as well as samples with lower percentages
of ER expression (such as tonsil). On-slide controls are ideal
because each slide is evaluated, and the control stays with
the slide. Regardless of the control type, the controls must
include samples fixed under conditions similar to those of
the test samples and incorporate tissues or cell lines with no
ER, low ER, and high ER and be as well standardized as
possible.107–110 While newer forms of standardized controls
are becoming more available, some of which are engineered
tissue-like materials with defined quantities of ER or PgR
included, long-standing experience has also been good for
cervix (as a strong ER-positive/PgR-positive control) and
tonsil (for PgR see: https://www.nordiqc.org/epitope.
php?id¼67 and for ER: https://www.nordiqc.org/
downloads/assessments/118_2.pdf).111–115 Tonsil has been
suggested as an ideal tissue type to include in external
controls to monitor the analytic sensitivity for ER and PgR
(Figure 4). Dispersed germinal center cells and the
squamous epithelium should be ER positive, but the B cells
in the mantle zones should be ER negative. In contrast to
ER, no nuclear PgR staining should be seen in tonsillar
tissue. Weak positive PgR staining in tonsil should result in
workup to determine if assay drift has occurred. Tumor
tissues with variable levels of expression can be useful as a
supplement to tonsil and control tissue with uniform ER/
PgR expression (such as cervix); however, it should be noted
that tumor tissue can be heterogeneous (creating different
staining patterns on a given level), and expression levels
may not be as well characterized. If changes in staining
results over time or between runs (drift) are noted
(especially the staining with low levels of ER expression),
the laboratory should undertake a careful analysis of its
procedures and any recent changes in test methods (eg, new
lot of antibody, change in clone, or modified reagents) prior
to issuing results to assess whether revalidation is required.
A guideline update dealing with IHC assay validation is
under development by CAP at the time of this publication
and should be deferred to once published. Prior to its
publication, the Expert Panel recommends applying previ-
ously recommended validation principles (as described by
Fitzgibbons et al12 and more recently Torlakovic et al13).
Do the Same Principles Apply to PgR Testing?
There is substantial evidence for higher rates of clinical
response to endocrine therapy in PgR-positive tumors
treated neoadjuvantly or in metastatic disease, but random-
ized trials in the adjuvant setting have revealed no difference
in the degree of benefit from adjuvant endocrine treatment
according to PgR status.11 The Expert Panel therefore
acknowledges that only ER should be used as a predictor
of benefit from adjuvant endocrine therapy. Because of this,
the Expert Panel discussed whether to continue to
recommend routine PgR testing in invasive breast cancers.
PgR levels can add prognostic information by helping to
stratify outcomes in the ER-positive population, with data
supporting that cases with lower or negative PgR expression
may have a worse prognosis.88–90,116 Used in combination
with ER (and other markers), PgR levels by IHC have been
used by various tools that estimate prognosis, such as the
IHC4 score, Magee equations, nomograms that predict the
21-gene recurrence score results, AJCC eighth edition
prognostic stage groupings, and various predictors of
response to neoadjuvant therapy.10,73,75,77–87
In addition, PgR may serve as an informal control for
samples that test ER negative but PgR positive (especially in
the absence of normal internal controls), since there are data
suggesting that this phenotype is frequently the result of
technical artifact.74 In the 2010 guideline, repeat testing in
cases with initial ER-negative/PgR-positive results was
suggested (not required), and the Expert Panel continues
 
are appropriately positive. If needed, testing another specimen that contains internal controls may be warranted for confirmation of ER status.’’ (‡) For
ER Low Positive results, include comment: ‘‘The cancer in this sample has a low level (1%–10%) of ER expression by IHC. There are limited data on
the overall benefit of endocrine therapies for patients with these results, but they currently suggest possible benefit, so patients are considered eligible
for endocrine treatment. There are data that suggest invasive cancers with these results are heterogeneous in both behavior and biology and often
have gene expression profiles more similar to ER-negative cancers.’’ Abbreviation: SOP, standard operating procedure.
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to support this recommendation (Table 1). Lastly, although
controversial as a result category, confirmed ER-negative/
PgR-positive samples may represent a rare biologic pheno-
type that may be offered endocrine therapies, although due
to the rarity of this result group, there are limited data to
support this.70,71,76
Given the utility of PgR testing for the above reasons, we
continue to recommend routine PgR testing of invasive
Figure 2. Case examples to illustrate stain
intensity and percentage interpretation. Ex-
amples of invasive cancers with various levels
of estrogen receptor (ER) expression. Magni-
fication of slides at (A) 350 and (B) 3200
from a case that was strongly and uniformly
positive (90%–100% cells staining, strong
intensity), at (C) 350 and (D) 3200 from a
case with weak-moderate intensity but almost
uniform positivity (70%–80% cells staining,
weak-moderate intensity), and at (E)350 and
(F) 3200 from a case that had between 1%
and 10% of cancer cells staining with weak
intensity (ER Low Positive). This low level of
expression is not easily seen on (E) low power
but is more readily seen on (F) moderate to
higher power. Magnification of slides at (G)
350 and (H) 3200 from an invasive cancer
with no ER expression (0% staining). Cases
with nuclear staining in , 1% of total cells in
the invasive carcinoma sample are also
classified as negative.
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breast cancers. Many thresholds have been used to
differentiate cancers on the basis of PgR expression for
prognostic purposes. This may reflect that PgR acts as a
more continuous variable for prognosis,72 and in the
absence of data consistently supporting alternative thresh-
olds or standards for PgR testing, we recommend using 1%
as a positivity threshold for PgR in invasive breast cancers
but also continue to recommend reporting the percentage
and intensity of cells staining. However, the low positive
reporting category and comment recommendation for
samples with 1% to 10% ER expression does not apply to
PgR. Otherwise, the same general recommendations that
apply to ER testing should also apply to PgR testing,
including participation in external proficiency testing by the
laboratory’s accrediting organization. However, laboratory
accreditation should primarily be dependent on a passing
grade for ER proficiency testing.
Clinical Question 2
What additional strategies can promote optimal perfor-
mance, interpretation, and reporting of IHC assays, partic-
ularly in cases with low to negative ER expression?
Recommendation 2.1.—Laboratories should include
ongoing quality control using SOPs for test evaluation prior
Figure 3. Internal controls. Examples of internal control analysis in estrogen receptor (ER) stains. (A) ER-negative invasive cancer (3200) with an
adjacent internal normal duct control (asterisks) with optimal staining (nuclear staining varying from weak to very strong with alternating clusters of
negative cells). (B) Unexpectedly weak stain result (3200) in both the grade 1 invasive cancer and normal duct internal controls (asterisks). This
result, although positive, raises concern about possible preanalytic variables affecting the assay or, if these are deemed appropriate, that the level of
analytic sensitivity of the assay may be too low (especially to detect ER–low positive results). (C) Case negative for ER expression (3400) both in the
invasive cancer and the internal control duct (asterisks). The assay should be repeated and an investigation for potential causes of negative internal
controls performed (including both preanalytic and analytic factors). If internal controls remain negative and this issue appears isolated to this
sample, the test should be reported as ‘‘cannot be determined’’ (indeterminate; uninterpretable because of negative internal controls, possible
preanalytic tissue preservation issues). (D) Invasive cancer with no ER staining (3200) and internal control columnar cell epithelium (asterisks) with
uniformly strong nuclear staining (as expected). These results help support that there were no serious issues with the preanalytic or analytic phases.
However, such strong positive internal controls are less optimal to evaluate how well the assay is able to detect low levels of ER expression (evaluation
of noncolumnar cell, normal duct controls is more optimal, as in panel A).
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to scoring (readout) and interpretation of any case as
defined in the checklist in Figure 1 (Type: Informal
consensus; Evidence quality: High; Strength of recommen-
dation: Strong).
Recommendation 2.2.—Interpretation of any ER result
should include evaluation of the concordance with the
histologic findings of each case. Clinicians should also be
aware of when results are highly unusual/discordant and
work with pathologists to attempt to resolve or explain
atypical reported findings; Table 3 is an aid in this process
(Type: Informal consensus; Evidence quality: High; Strength
of recommendation: Strong).
Recommendation 2.3.—Laboratories should establish and
follow anSOP stating the steps the laboratory takes to confirm
or adjudicate ER results for cases with weak stain intensity or
 10% of cells staining; see Supplemental Digital Content
Data Supplement 2, Figure 1 (at www.archivesofpathology.
org in the May 2020 table of contents) provides an example
SOP (Type: Informal consensus; Evidence quality: High;
Strength of recommendation: Strong).
Recommendation 2.4.—The status of internal controls
should be reported for cases with 0% to 10% staining. For
cases with these results without internal controls present and
with positive external controls, an additional report comment
is recommended (Table 2) (Type: Informal consensus;
Evidence quality:High; Strength of recommendation: Strong).
Literature Review and Analysis.—Recommendations 2.1
and 2.2 re-emphasize elements of the original 2010 guideline.
Recommendation 2.3 is a new focus of this update because of
concerns about test validity and reproducibility for cases with
weak-intensity, low-level, or negative ER staining. The
updated recommendations focus on increased standardiza-
tion in the workup of these weak, low, or negative ER cases
with the development of a specific SOP to confirm or
adjudicate the result (Figure 1). This is noted to already be
standard best practice in many laboratories.
Figure 1 reviews initial steps in the evaluation of any ER
IHC and includes the quality control checklist. Cases with
moderate-strong stain intensity and . 10% of cells staining
are considered to have robust, reportable results as long as
they are considered concordant with histology (Table 3) and
no checklist issues are identified. For cases with weak stain
intensity or  10% of nuclei staining, additional steps
should be taken to confirm or adjudicate the validity of the
results, and correlation with histology should be performed.
Steps to consider including in an SOP are shown in Figure
1, and an example of a more detailed SOP for these
purposes is available as Supplemental Digital Content Data
Supplement 2, Figure 1. Because of previously identified
factors involved in false-negative results such as negative or
absent internal controls, evaluation of controls is considered
Figure 4. External controls. Optimal external (ideally on-slide) controls
for both estrogen receptor (ER) and progesterone receptor (PgR) should
include multiple tissues, including ones with expected strong staining,
lower limit of detection levels, and negative controls; tonsil and cervix
have been used to meet these criteria. (A) Tonsil tissue (3200) with
optimal staining for ER to ensure an appropriate low limit of detection;
dispersed germinal center cells and the squamous epithelium should be
ER positive, but the B cells in the mantle zones should be ER negative.
 
In contrast to ER, no nuclear PgR staining should be seen in tonsillar
tissue. Weak-positive PgR staining in tonsil should result in workup to
determine if assay drift has occurred. (B) PgR variably staining the basal
layer of the squamous mucosa (3200) as expected (this staining should
ensure an appropriate low limit of detection for PgR). Stromal cells stain
strongly for both ER and PgR. ER should stain the squamous mucosa
more uniformly (not just the basal layer), with at least moderate to
strong stain intensity. (C) PgR staining (3200) should also be positive in
the endocervical columnar epithelial cells (with some variability
expected). ER should stain almost all endocervical columnar epithelial
cells. Of note, it should be taken into consideration that hormone
receptor staining of cervical tissue may be reduced in tissue from
postmenopausal women.
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an essential part of this process.118 If internal controls are
negative, or there are no internal controls and the external
positive controls do not have appropriate staining, the assay
has failed and needs to be troubleshot. In addition,
correlation with any prior patient-specific ER results on a
breast cancer would be considered relevant. There are data
to support that second reviews and digital quantitative
image analysis reads can be used to improve reproducibility
and accuracy in a pathologist’s scoring (readout) and
interpretation, so these can be useful components of an
SOP for these cases; however, the Expert Panel acknowl-
edges that current data on these topics are not specific
enough to distinguish ER–low positive from ER-negative
cases.61–69,119–121 Additional comments to include in reports
for samples of invasive carcinoma that are ERlow positive
(1%–10%) or cancers (either invasive or DCIS) with  10%
staining without internal controls present (but positive
external controls) are listed in Table 2.
Clinical Question 3
Are other ER expression assays acceptable for identifying
patients likely to benefit from endocrine therapy?
Recommendation 3.—Validated IHC is the recommended
standard test for predicting benefit from endocrine therapy.
No other assay types are recommended as the primary
screening test for this purpose (Type: Evidence based;
Evidence quality: High; Strength of recommendation: Strong).
Literature Review and Analysis.—The Expert Panel re-
viewed the existing evidence and concluded that data are
insufficient at this time to recommend newer methods of ER
testing as alternatives to IHC for the purposes of determin-
ing ER status or selecting which patients are likely to benefit
from endocrine therapy. One issue that was apparent was
the lack of data from randomized clinical trials using these
assays and platforms to select patients for treatment with
endocrine therapy versus observation.
However, the Expert Panel recognizes that there are
limited avenues for validation of new assays and platforms,
as these types of prospective clinical trials are not likely to be
conducted. While there are multiple studies that compare
messenger RNA (mRNA) with IHC with relatively good
agreement, the Expert Panel agreed that this was insufficient
to recommend the assays.
Some panel-based gene-expression assays, like Oncotype
DX (Genomic Health, Redwood City, CA), have already been
incorporated into standard treatment algorithms for IHC ER-
positive cancers as a tool to assess the likelihood of clinical
benefit offered by chemotherapy when added to endocrine
therapy.122–125 Assays like Oncotype DX, Mammaprint (Agen-
dia, Irvine, CA), the Prosignia Breast Cancer Prognostic Gene
Signature Assay (PAM-50; Prosignia NanoString Technolo-
gies, Seattle, WA), EndoPredict (Myriad Genetics, Salt Lake
City, UT), and the Breast Cancer Index (Biotheranostics, San
Diego, CA) also offer prognostic information regarding the
risk of recurrence in patients treated with endocrine therapy,
and they have improved the ability to understand the biologic
behavior of ER-positive breast cancer as defined by standard
IHC measures. In most cases, studies of these new assays
established their clinical validity regarding their prognostic
utility (outcome after a therapy) but were limited in their
predictive utility in identifying patients expected to benefit
specifically from endocrine treatment.126,127
Some of the limited data on benefit from endocrine
treatment in relation to ER mRNA expression come from a
retrospective study of the NSABP B-14 trial of tamoxifen
versus no endocrine therapy. This study showed that in a
selected population of patients who were ER positive by
LBA, higher ESR1 expression by the Oncotype DX assay was
the strongest linear predictor of tamoxifen benefit, with a
significant interaction with treatment.60 However, specific
ER mRNA expression thresholds to predict potential benefit
from endocrine therapy as a screening test for all breast
cancers were not developed in this study, since ERnegative
cases by LBA were not enrolled in NSABP B-14.
Therefore, while new methods of ER testing may offer
some advantages over IHC methods (such as producing a
quantitative, highly reproducible result), data on their ability
to predict endocrine therapy benefit for all cancers as an
initial screening test are limited. In addition, a disadvantage
of most current mRNA-based methods is that intermixed
noncancer tissues can contribute to test results, which may
particularly affect cases close to the positive threshold (eg, an
IHC ER–low positive result testing ER negative by quantita-
tive mRNA due to dilution by intermixed noncancer ER-
negative tissue). There are very limited data on patients with
tumors that are deemed ERlow positive by IHC and tested
with newer alternative assays. Test comparison studies
suggest that cases that have low levels of ER expression by
IHC (but  1%) are more frequently deemed ER negative by
mRNA assays and have variable ESR1 expression across IHC
categories (in one study, 24% of cases were considered ER
positive by mRNA expression if IHC 1%–9% and 92% if IHC
. 10%).59,106 Therefore, ER expression of  1% by IHC
remains the current standard to identify patients who could
benefit from endocrine therapy in breast cancer, and a
negative quantitative mRNA ER result (eg, on Oncotype DX
testing) should not negate an IHC-positive result.
Clinical Question 4
Should DCIS be routinely tested for hormone receptors?
Recommendation 4.—ER testing in cases of newly
diagnosed DCIS (without associated invasion) is recom-
Table 3. Invasive Breast Cancer Histopathologic Concordance With ER Staining
Highly Unusual ER-Negative Results Highly Unusual ER-Positive Results
Low-grade invasive carcinomas of no special type
(also known as invasive ductal carcinoma)
Metaplastic carcinomas of all subtypes
Lobular carcinomas (classic type) Adenoid cystic carcinomas and other salivary gland–like carcinomas of the breast
Pure tubular, cribriform, or mucinous carcinomas Secretory carcinoma
Encapsulated papillary and solid papillary carcinomas Carcinomas with apocrine differentiation
NOTE. If a result is considered highly unusual/discordant, additional steps should be taken to check the accuracy of the histologic type or grade as
well as the preanalytic and analytic testing factors. This workup may include second reviews and repeat testing. If all results appear valid, the result
can be reported with a comment noting that the findings are highly unusual and testing of additional samples may be of value to confirm the findings.
Abbreviation: ER, estrogen receptor.
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mended to determine potential benefit of endocrine
therapies to reduce risk of future breast cancer. PgR testing
is considered optional (Type: Evidence based; Evidence
quality: Intermediate; Strength of recommendation: Mod-
erate).
Literature Review and Analysis.—In 2010, the Expert Panel
acknowledged that newly diagnosed DCIS cases (in the
absence of invasion) were commonly being tested for ER
and PgR based largely on early but unpublished results from
the NSABP B-24 trial.128 Because of the limited data
available at the time, the Expert Panel did not make a
formal recommendation, leaving it up to patients and their
physicians to decide on testing. Subsequently, in 2012, the
subset analysis of the NSABP B-24 clinical trial was
published comparing tamoxifen versus placebo after lump-
ectomy and radiation therapy; these trial data showed a
significant reduction in relative risk of subsequent breast
cancer restricted to patients with ER-positive DCIS at 10
years of follow-up (hazard ratio [HR], 0.49; P ¼ .001).58 In
the UK/ANZ randomized clinical trial examining endocrine
therapy in DCIS (v no endocrine therapy), long-term
follow-up data showed that tamoxifen reduced the inci-
dence of all new breast events in excised DCIS treated with
radiation therapy. However, these cases were untested for
ER.57,129 In another phase III clinical trial, women with
intraepithelial neoplasia, including ER-positive DCIS, were
randomly assigned to receive low-dose tamoxifen or
placebo. After a median follow-up of 5.1 years, tamoxifen
reduced the incidence of new DCIS or invasive breast cancer
(HR, 0.48; 95% CI, 0.26 to 0.92).130 Retrospective data from
single-institution studies also appear to support a higher
risk of recurrence in patients with ER-positive DCIS who
were not treated with endocrine therapy.55,56 However, it
should be acknowledged that there are currently no data
indicating that endocrine-based therapy in the setting of
newly diagnosed DCIS has a significant impact on overall
survival. Therefore, the decision to use endocrine therapy
will depend on individual patient goals and discussion with
their clinical care team, but patients should be aware of
primary risk reduction options based on the ER status of
their DCIS.
Based on the current evidence, the Expert Panel now
recommends ER testing in DCIS to guide discussions about
adjuvant endocrine therapy. The ER status of newly
diagnosed DCIS should be reported when no invasive
cancer is present.
Data on whether PgR testing in DCIS adds predictive or
prognostic value beyond that of ER alone are currently
lacking. In the NSAPB B-24 trial, ER alone was more
predictive than combined ER and PgR statuses or PgR status
of DCIS for tamoxifen benefit, as patients with ER-positive/
PgR-negative DCIS still received benefit, although subsets
were small. However, contrary to the prognostic value seen
for PgR testing in invasive cancers, studies have not shown
significant differences in outcome between ER-positive/
PgR-positive and ER-positive/PgR-negative statuses in
patients with DCIS.55,56 Given that there are no data
currently supporting the prognostic or predictive value of
PgR testing in DCIS independent of ER, the Expert Panel
considers PgR testing of DCIS to be optional.
EXTERNAL REVIEW AND OPEN COMMENT
The draft recommendations were released to the public
for open comment from April 15 through April 29, 2019.
Response categories of ‘‘Agree’’ and ‘‘Disagree’’ were
captured for every proposed recommendation, with 163
written comments received.
More than 80% of the 163 respondents agreed to 8 of the
10 questions pertaining to the recommendations and 2
questions fell below an 80% agreement rate. Expert Panel
members reviewed comments from all sources and deter-
mined to revise the recommendations that did not receive at
least 80% agreement for clarity. All changes were incorpo-
rated prior to ASCO CPGC and CAP review and approval.
ADDITIONAL RESOURCES
More information, including a supplement with evidence
tables, slide sets, and clinical tools and resources, is available
atwww.asco.org/breast-cancer-guidelines. TheMethodology
Manual (available at www.asco.org/guideline-methodology)
provides additional information about the methods used to
develop this guideline. Patient information is available at
www.cancer.net.
EDITOR’S NOTE
American Society of Clinical Oncology (ASCO) clinical
practice guidelines provide recommendations, with com-
prehensive review and analyses of the relevant literature for
each recommendation. Additional information, including a
supplement with additional evidence tables, slide sets,
clinical tools and resources, and links to patient information
at www.cancer.net, is available at www.asco.org/breast-
cancer-guidelines.
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(http://ascopubs.org/doi/10.1200/JCO.2018.79.2697)
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